Transdiagnostic internet-based and mobile-supported intervention for the treatment of anxiety disorders

Transdiagnostic internet-based and mobile-supported intervention for the treatment of anxiety disorders - ICare - Coping with Anxiety

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012656

Enrollment

114

Registered

2018-10-29

Start date

2018-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F40 F41.9 F41.1 F32 F41.0

Interventions

Group 1: Intervention group: Guided self-help online training consisting of 7 modules, which take about 45-60 minutes each to complete with an additional booster session 4 weeks after completion of th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Minimum age 18; Signed consent form; Clinical diagnosis of anxiety disorder determined by diagnostic interview

Exclusion criteria

Exclusion criteria: Acute suicidal tendency determined by initial diagnostic interview; unwilling to sign the consent form; self-report on present psychosis or dissociative symptoms; bipolar disorder in the past or present; current major depressive disorder; psychotherapeutic treatment in the previous 6 months or waitlist

Design outcomes

Primary

Measure	Time frame
Symptom reduction of symptom severity anxiety disorders (Hamilton Anxiety Rating Scale, HAM-A, Hamilton, 1959), at postassessment	—

Secondary

Measure	Time frame
Time to disorder onset of any depression and/or anxiety disorder within a follow-up period after baseline, determined by clinical, diagnostic telephone interviews: • Psychopathology (Sections of Mini international Neuropsychiatric Interview, Mini 6.0, Sheehan, Lecrubier, 2010) at T1 baseline (pre), 6 and 12 months Follow-up (6 & 12 M-F-U); • Depressive symptoms (Inventory of depressive Symptomatology QIDS-C16, Rush, et al., 1996), at pre, post, 6 & 12 M-F-U; • Anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A, Hamilton, 1959), at pre, post, 6 & 12 M-F-U. By self-report in questionnaires: • Symptom severity (e.g. depression, anxiety) by self-report in questionnaires (Center for Epidemiologic Studies Depression Scale, CES-D, Radloff, 1977; General Anxiety Disorder Measurement, GAD-7, Spitzer, Kroenke, Williams, et al., 2006) at T0, peri-treatment (peri, 4 weeks), post, 6 & 12 M-F-U; • Depressive symptoms (Patient Health Questionnaire, PHQ-9, Kroenke, Spitzer, Williams, 2001) at pre, peri, post, 6 & 12 M-F-U; • Sociodemographics (self developed) at T0 (sign-up) • Mental health (self developed) at T0 (sign-up) • Alcohol use (The Alcohol Use Disorder Identification Test, AUDIT-C, Babor et al., 2001) at pre, peri, post, 6 & 12 M-F-U; • Quality of Life (WHO-Five Wellbeing Index, WHO-5, WHO, 1998) at pre, post, 6 & 12 M-F-U; • Quality of life (EuroQol, EQ-5D, EuroQol Group, 1995) at pre, post, 6 & 12 M-F-U; • Quality of life (Assesment Quality of Life, AQol-8D, Hawthorne, Richardson & Osborne, 1999) at pre, post, 6 & 12 M-F-U; • Cost effectiveness (Client Service Receipt Inventory, CSRI, Beecham & Knapp, 1992) at pre, 6 & 12 M-F-U; • Training expectations (Credibility/Expectancy Questionnaire, CEQ, Devilly & Borkovec, 2000) at pre; • Negative effects of training (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP, Ladwig, Rief & Nestoriuc, 2014) at post; • Training satisfaction (Client Satisfaction Questionnaire, CSQ-8, Larsen, Attkisson, Hargreav	—

Measure

Time frame

Time to disorder onset of any depression and/or anxiety disorder within a follow-up period after baseline, determined by clinical, diagnostic telephone interviews: • Psychopathology (Sections of Mini international Neuropsychiatric Interview, Mini 6.0, Sheehan, Lecrubier, 2010) at T1 baseline (pre), 6 and 12 months Follow-up (6 & 12 M-F-U); • Depressive symptoms (Inventory of depressive Symptomatology QIDS-C16, Rush, et al., 1996), at pre, post, 6 & 12 M-F-U; • Anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A, Hamilton, 1959), at pre, post, 6 & 12 M-F-U. By self-report in questionnaires: • Symptom severity (e.g. depression, anxiety) by self-report in questionnaires (Center for Epidemiologic Studies Depression Scale, CES-D, Radloff, 1977; General Anxiety Disorder Measurement, GAD-7, Spitzer, Kroenke, Williams, et al., 2006) at T0, peri-treatment (peri, 4 weeks), post, 6 & 12 M-F-U; • Depressive symptoms (Patient Health Questionnaire, PHQ-9, Kroenke, Spitzer, Williams, 2001) at pre, peri, post, 6 & 12 M-F-U; • Sociodemographics (self developed) at T0 (sign-up) • Mental health (self developed) at T0 (sign-up) • Alcohol use (The Alcohol Use Disorder Identification Test, AUDIT-C, Babor et al., 2001) at pre, peri, post, 6 & 12 M-F-U; • Quality of Life (WHO-Five Wellbeing Index, WHO-5, WHO, 1998) at pre, post, 6 & 12 M-F-U; • Quality of life (EuroQol, EQ-5D, EuroQol Group, 1995) at pre, post, 6 & 12 M-F-U; • Quality of life (Assesment Quality of Life, AQol-8D, Hawthorne, Richardson & Osborne, 1999) at pre, post, 6 & 12 M-F-U; • Cost effectiveness (Client Service Receipt Inventory, CSRI, Beecham & Knapp, 1992) at pre, 6 & 12 M-F-U; • Training expectations (Credibility/Expectancy Questionnaire, CEQ, Devilly & Borkovec, 2000) at pre; • Negative effects of training (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP, Ladwig, Rief & Nestoriuc, 2014) at post; • Training satisfaction (Client Satisfaction Questionnaire, CSQ-8, Larsen, Attkisson, Hargreav

—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactAnna-Carlotta Zarski

Lehrstuhl fu¨r Klinische Psychologie und Psychotherapie (KliPs)Friedrich-Alexander-Universität Erlangen-Nu¨rnberg (FAU)

anna-carlotta.zarski@fau.de09131 - 85 - 67570

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026